Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
Shares of Amgen (AMGN) are down $6.62, or 2%, to $282.40 in after-hours trading.Maximize Your Portfolio with Data Driven Insights:Leverage the ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Industrial company 3M ( MMM 1.15%) was the index's top performer in January with a 17.9% gain. Part of the stock's movement ...
Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...
Investor's Business Daily on MSN3h
Amgen Skids On A Surprise Setback For One Of Its Obesity DrugsAmgen stock skidded late Tuesday after the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback